- Evonik has expanded its EUDRACAP portfolio with a new capsule designed for delivering sensitive active ingredients to the ileo-colonic region.
- The EUDRACAP colon capsule will support the delivery of live biotherapeutic products (LBPs) and other complex drugs, with a GMP-grade version in development.
Evonik has announced the expansion of its EUDRACAP portfolio with the introduction of a new functional capsule designed to deliver sensitive active ingredients, such as live biotherapeutic products (LBPs), to the ileo-colonic region. The new capsule, EUDRACAP colon, aims to support the treatment of a wide range of diseases by enabling targeted drug delivery to this specific part of the gastrointestinal tract.
Currently available in technical grade, the EUDRACAP colon capsule is set to streamline the development of oral drugs by reducing formulation complexity. A GMP-grade version of the product is also under development to meet broader market needs. The capsule leverages Evonik’s EUDRAGIT coatings, which offer tailored release profiles based on customer requirements.
Axel Schroeder, Head of Oral Drug Delivery Solutions at Evonik, commented, “Drawing on decades of know-how, we are working with customers on new paths for ileo-colonic delivery. Our EUDRACAP platform is a testament to strong innovation and growth, and we are delighted to expand this portfolio.”
The EUDRACAP colon capsule can be used to deliver a range of sensitive active ingredients, including oral biologics, proteins, peptides, and nucleotides. This flexibility makes it suitable for drugs treating conditions such as obesity, HIV, cystic fibrosis, colorectal cancer, and infections, where targeted delivery to the ileo-colonic region is crucial.
Overview of outsourcing trends 
